Antiphospholipid syndrome updating;Actualización del síndrome antifosfolipídico

Medicina Clinica

Volumn 121, Issue 12, 2003, Pages 459-471

  Orts, Juan Antonio ^a   Zúñiga, Ángel ^a   Orera, María ^b  

^a HOSPITAL DE LA RIBERA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Anti beta2 glycoprotein; Anticardiolipin antibody; Antiphospholipid syndrome; Lupus anticoagulant; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; CARDIOLIPIN ANTIBODY; COMPLEMENT FACTOR H; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ATHEROSCLEROSIS; DIFFERENTIAL DIAGNOSIS; FETUS WASTAGE; GENETIC DISORDER; HUMAN; INFECTION; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RECURRENT ABORTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0242473601     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052794     Document Type: Review

References (106)

1. Hughes GR. Thrombosis, abortion, cerebral disease and lupus anticoagulant. BMJ 1983;287:1088-9.
2. Harris EN, Gharavi AE, Boey ML, Patel BM, Maackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211-4.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
4. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol 1992;19:508-12.
5. Shoenfeld Y. Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome. Trends Immunol 2003;24:2-4.
6. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 2000;27:2817-21.
7. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
8. Alarcón-Segovia D, Cabral AR. The concept and classification of antiphospholipid/cofactor syndromes. Lupus 1996;5:364-7.
9. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
10. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000;43:440-3.
11. Wilson WA, Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:499-505.
12. Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001;10:457-60.
13. Caso V, Panarelli P, Albi E, Viola-Magni MP, Parnetti L, Gallai V. Phospholipid autoantibodies: time for a new immuno-assay? Clin Exp Hypertens 2002;24:511-6.
14. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002;90:29-37.
15. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109:797-804.
16. Gharavi AE, Pierangeli SS, Espinola RG. Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002;46:545-52.
17. Capila I, Hernaiz MJ, Mo YD, Mealy TR, Campos B, Dedman JR, et al. Annexin V-heparin oligosaccharide complex suggests heparan sulfate-mediated assembly on cell surfaces. Structure (Camb) 2001;9:57-64.
18. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
19. Disponible en: http://www.med.ub.es/MIMMUN/FORUM/INMUNOGE. HTM
20. Galeazzi M, Sebastiani GD, Tincani A, Piette JC, Allegri F, Morozzi G, et al. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000;9:47-55.
21. Lutters BC, De Groot PG, Derksen RH. Beta 2 glycoprotein I, a key player in the antiphospholipid syndrome. Isr Med Assoc J 2002;4:958-62.
22. De Groot PG, Bouma B, Lutters BC, Derksen RH. Lupus anticoagulant in cardiovascular diseases: the role of beta2-glycoprotein I. Ann Med 2000;32(Suppl 1):32-6.
23. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med 2002;126:1424-9.
24. Singh AK. Immunopathogenesis of the antiphospholipid antibody syndrome: an update. Curr Opin Nephrol Hypertens 2001;10:355-8.
25. Steinerova A, Racek J, Stozicky F, Zima T, Fialova L, Lapin A. Antibodies against oxidized LDL-theory and clinical use. Physiol Res 2001;50:131-41.
26. Lieby P, Soley A, Levallois H, Hugel B, Freyssinet JM, Cerutti M, et al. The clonal analysis of anticardiolipin antibodies in a single patient with primary antiphospholipid syndrome reveals an extreme antibody heterogeneity. Blood 2001;97:3820-8.
27. Reutelingsperger CP. Annexins: key regulators of haemostasis, thrombosis and apoptosis. Thromb Haemost 2001;86:413-9.
28. Tomer A. Antiphospholipid antibody syndrome: rapid, sensitive, and specific flow cytometric assay for determination of anti-platelet phospholipid autoantibodies. J Lab Clin Med 2002;139:147-54.
29. Sebire NJ, Regan L, Rai R. Biology and pathology of the placenta in relation to antiphospholipid antibody-associated pregnancy failure. Lupus 2002;11:641-3.
30. Espinola RG, Pierangeli SS, Ghara AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518-22.
31. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003;207:29-36.
32. Burcoglu-O'Ral A, Erkan D, Asherson R. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J. Rheumatol 2002;29:2006-11.
33. Kobayashi K, Kishi M, Atsumi T, Bertolaccini M, Makino H, Sakairi N, et al. Circulating oxidized LDL forms complexes with beta 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003: Disponible en: http://www.jlr.org
34. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003;207:13-6.
35. Gennari LC, Blanco AN, Alberto MF, Grosso SH, Peirano AA, Lazzari MA. Antiphospholipid antibodies impact the protein C (PC) pathway behavior. Am J Hematol 2002;71:128-30.
36. Muñoz-Rodríguez FJ, Reverter JC, Font J, Tassies D, Espinosa G, Cervera R, et al. Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus. Lupus 2002;11:730-5.
37. Adams MJ, Donohoe S, Mackie IJ, Machin SJ. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001;114:375-9.
38. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods VL Jr, Le DT, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001;167:7192-8.
39. Takeuchi R, Atsumi T, leko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002;119:781-8.
40. Ogunyemi D, Cuellar F, Ku W, Arkel Y. Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein a levels and venous thromboembolism in pregnancy. Am J Perinatol. 2003;20:17-24.
41. Erkan D, Zhang HW, Shriky RC, Merrill JT. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002;11:215-20
42. Avivi I, Lanir N, Hoffman R, Brenner B. Hyperhomocysteinemia is common in patients with antiphospholipid syndrome and may contribute to expression of major thrombotic events. Blood Coagul Fibrinolysis 2002;13:169-72.
43. Wasmuth JC, Oliver y Minarro D, Homrighausen A, Leifeld L, Rockstroh JK, Sauerbruch T, et al. Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accuracy of 23 methods studied by variation in ROC curves with number of clinical manifestations. Clin Chem 2002;48:1004-10.
44. Galli M, Barbui T. Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome. Clin Chem 2001;47:985-7.
45. Chi HS. Recent advances in the diagnosis of antiphospholipid syndrome. Int J Hematol 2002;76(Suppl 2):47-51.
46. Ames PR, Iannaccone L, De lasio R, Brancaccio V. Improved confirmation of weak lupus anticoagulants by employing sensitive and insensitive reagents to the lupus anticoagulant. Blood Coagul Fibrinolysis 2001;12:563-7.
47. Jacobsen EM, Barna-Cier L, Taylor JM, Tripiett DA, Wisloff F. The evaluation of clotting times in the laboratory detection of lupus anticoagulants. Thromb Res 2001;104:275-82.
48. Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol 2001;44:48-57.
49. Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001;28:2637-43.
50. Lee SS, Cho ML, Joo YS, Kim WU, Hong YS, Min JK, et al. Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol 2001;28:520-4.
51. Audrain MA, El-Kouri D, Hamidou MA, Mioche L, Ibara A, Langlois ML, et al. Value of autoantibodies to beta(2)-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:550-3.
52. Previtali S, Barbui T, Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. Thromb Haemost 2002;88:729-32.
53. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002;11:269-75.
54. McIntyre JA, Wagenknech DR, Waxman DW. Frequency and specificities of antiphospholipid antibodies (aPL) in volunteer blood donors. Immunobiology 2003;207:59-63.
55. Wahl DG, Guillemin F, De Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998;7:15-22.
56. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002;119:1005-10.
57. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531.
58. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost 2002;87:802-7.
59. Ruiz-Irastorza G. Síndrome de Hughes y trombosis: el debate continúa. Med Clin (Barc) 2002;118:97-8.
60. Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus 2002;11:4-10.
61. Disponible en: http://www.kenes.com/aps/
62. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al (Euro-Phospholipid Project Group). Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
63. Quintero-del-Río AI. Antiphospholipid antibodies in pediatrics. Curr Rheumatol Rep 2002;4:387-91.
64. Asherson RA, Shoenfeld Y. Human immunodeficiency virus infection, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol 2003;30:214-9.
65. Zachou K, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselis N, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003;33:161-8.
66. Espinosa G, Cervera R, Font J. El pulmón en el síndrome antifosfolipídico. Arch Bronconeumol 2002;38:27-32.
67. Espinosa G, Font J, García-Pagán JC, Tassies D, Reverter JC, Gaig C, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine (Baltimore) 2001;80:345-54.
68. Muñoz-Rodríguez FJ, Reverter Calatayud JC, Font Franco J, Espinosa Garriga G, Tassies Penella D, Ingelmo Morin M. Cardiopatía valvular en pacientes con síndrome antifosfolipídico. Rev Clin Esp 2002;202:529-33.
69. Lev S, Shoenfeld Y. Cardiac valvulopathy in the antiphospholipid syndrome. Clin Rev Allergy Immunol 2002;23:341-8.
70. McMillan E, Martin WL, Waugh J, Rushton I, Lewis M, Clutton-Brock T, et al. Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome. Lupus 2002;11:392-8.
71. Henning BF, Grone HJ, Tepel M, Buchner N, Kirchner J, Zidek W. A rare cause of pulmonary-renal syndrome. Nephron 2002;91:516-20.
72. Bayraktar Y, Tanaci N, Egesel T, Gokoz A, Balkanci F. Antiphospholipid syndrome presenting as portopulmonary hypertension. J Clin Gastroenterol 2001;32:359-61.
73. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000;79:57-68.
74. Brey RL. Diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome. Journal of Autoimmunity 2000;15:133-8.
75. Chapman J, Abu-Katash M, Inzelberg R, Yust I, Neufeld MY, Vardinon N, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 2002;203-204:81-4.
76. Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002;11:736-43.
77. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999;78:209-19.
78. Karim MY, Alba P, Tungekar MF, Abbs IC, Khamashta MA, Hughes GR, et al. Hypertension as the presenting feature of the antiphospholipid syndrome. Lupus 2002;11:253-6.
79. Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. «Black swan in the kidney» renal involvement in the antiphospholipid antibody syndrome. Kidney Int 2002;62:733-44.
80. Espinosa G, Santos E, Cervera R, Piette JC, De la Red G, Gil V, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) 2003;82:106-18.
81. Martín H, Khamashta MA. Trombocitopenia en el síndrome antifosfolipídico. Med Clin (Barc) 1998;111:776-8.
82. Levy J, Baumgarten A, Rosenthal G, Rabinowitz R, Lifshitz T. Consecutive central retinal artery and vein occlusions in primary antiphospholipid syndrome. Retina 2002;22:784-6.
83. Nogueira Goriba A, Martín Sánchez MD. Manifestaciones oftalmológicas del síndrome antifosfolipídico primario. Rev Clin Esp 2001;201:39-40.
84. Erkan D. The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: a review of the literature and management strategies. Curr Rheumatol Rep 2002;4:379-86.
85. Carbone J, Sarmiento E, Segovia P, Rodríguez-Mahou M, Rodríguez-Molina JJ, Fernández-Cruz E. Anticuerpos antifosfolipídicos y evolución a conectivopatía: estudio de seguimiento de mujeres con abortos recurrentes. Med Clin (Barc) 2002;119:681-5.
86. Hornstein MD, Davis OK, Massey JB, Paulson RJ, Collins JA. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000;73:330-3.
87. Backos M, Rai R, Regan L. Antiphospholipid antibodies and infertility. Hum Fertil (Camb) 2002;5:30-4.
88. Balasch J, Cervera R. Reflections on the management of reproductive failure in the antiphospholipid syndrome - the clinician's perspective. Lupus 2002;11:467-77.
89. Thuerl C, Altehoefer C, Spyridonidis A, Laubenberger J. Imaging findings in the rare catastrophic variant of the primary antiphospholipid syndrome. Eur Radiol 2002;12:545-8.
90. Erkan D, Erel H, Yazici Y, Prince MR. The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J Rheumatol 2002;29:2658-9.
91. Triplett DA, Asherson RA. Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 2000;65:154-9.
92. Ihle BU, Oziemski P. Multi-organ failure secondary to catastrophic antiphospholipid syndrome. Anaesth Intensive Care 2002;30:82-5.
93. Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Opin Hematol 2000;7:325-9.
94. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924-9.
95. Harris EN, Peirangeli SS, Gharavi AE. Antiphospholipid syndrome: diagnosis, pathogenesis, and management. J Med Assoc Ga 2002;91:31-4.
96. Wahl DG, Bounameaux H, De Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000;160:2042-8.
97. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002;162:1164-9.
98. Roubey RA.Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 2002;14:238-42.
99. Ahmed S, Karim A, Patel D, Siddiqui R, Mattana J. Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome. Am J Med Sci 2002;324:279-80.
100. Ginsberg JS, Greer I, HirshJ. Use of antithrombotic agents during pregnancy. Chest 2001;119:122S-31S.
101. Derksen RH, De Groot PG, Nieuwenhuis HK, Christiaens GC. How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis 2001;60:1-3.
102. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13.
103. Huong DL, Wechsler B, Bletry O, Vauthier-Brouzes D, Lefebvre G, Piette JC. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 2001;28:2025-30.
104. Tektonidou MG, Ioannidis JP, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM 2000;93:523-30.
105. Amigo MC.Prognosis in antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:661-9.
106. Williams FM, Chinn S, Hughes GR, Leach RM. Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome. Ann Rheum Dis 2002;61:414-21.